{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T00:07:28Z","timestamp":1777853248343,"version":"3.51.4"},"reference-count":15,"publisher":"SAGE Publications","license":[{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["J Int Assoc Provid AIDS Care"],"published-print":{"date-parts":[[2022,1]]},"abstract":"<jats:p>Background: Tuberculosis (TB) is the leading cause of death in human immunodeficiency virus (HIV)-infected people worldwide. Currently there are no studies examining the use of Rifabutin (RBN) and Dolutegravir (DTG) in co-infected persons. This is a case series of 4 co-infected patients receiving both agents who underwent Pharmacokinetic (PK) analysis. Methods and Results: This is a retrospective chart review study of four patients diagnosed with both HIV and TB, receiving RBN and DTG and undergoing therapeutic drug monitoring. All 4 cases had lower than expected DTG concentrations at least once, including those on the current recommended dose of DTG with RBN, and even those receiving higher doses. Conclusions: Given the frequency of low DTG and RBN concentrations, therapeutic drug monitoring (TDM) for these drugs is advisable. Prospective clinical studies are needed to further determine the PK interactions between RBN and DTG, and virologic response to treatment.<\/jats:p>","DOI":"10.1177\/23259582221111077","type":"journal-article","created":{"date-parts":[[2022,8,26]],"date-time":"2022-08-26T15:00:22Z","timestamp":1661526022000},"update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":1,"title":["Effect of Rifabutin in Dolutegravir Dosing: A Case Series"],"prefix":"10.1177","volume":"21","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3822-0669","authenticated-orcid":false,"given":"Maria A.","family":"Mendoza","sequence":"first","affiliation":[{"name":"Department of Medicine, University of Miami, Miami, FL, USA"},{"name":"Department of Infectious Diseases, Mayo Clinic, Rochester, MN, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mohammad H.","family":"Alshaer","sequence":"additional","affiliation":[{"name":"Infectious Disease Pharmacokinetics Lab, College of Pharmacy, and Emerging Pathogens Institute, University of Florida, Miami, FL, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giovanni","family":"Roldan","sequence":"additional","affiliation":[{"name":"Department of Medicine, University of Miami, Miami, FL, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jose Guillermo","family":"Castro","sequence":"additional","affiliation":[{"name":"Division of Infectious Diseases, University of Miami Miller School of Medicine, Miami, FL, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David","family":"Ashkin","sequence":"additional","affiliation":[{"name":"Bureau of Communicable Diseases, TB Control Section Florida Department of Health, Tallahassee, FL, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Charles A.","family":"Peloquin","sequence":"additional","affiliation":[{"name":"Bureau of Communicable Diseases, TB Control Section Florida Department of Health, Tallahassee, FL, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Catherine V.","family":"Boulanger","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases, Mayo Clinic, Rochester, MN, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"179","published-online":{"date-parts":[[2022,8,26]]},"reference":[{"key":"bibr1-23259582221111077","volume-title":"Guidelines for treatment of drug-susceptible tuberculosis and patient care, 2017 update","author":"Geneva: World Health Organization","year":"2017"},{"key":"bibr2-23259582221111077","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciw376"},{"key":"bibr3-23259582221111077","unstructured":"World Health Organization. WHO recommends dolutegravir as preferred HIV treatment option in all populations. Accessed July 30, 2020."},{"key":"bibr4-23259582221111077","doi-asserted-by":"publisher","DOI":"10.2165\/00003088-200140050-00002"},{"key":"bibr5-23259582221111077","doi-asserted-by":"publisher","DOI":"10.1097\/QAI.0b013e318276cda9"},{"key":"bibr6-23259582221111077","doi-asserted-by":"publisher","DOI":"10.1002\/jia2.25333"},{"key":"bibr7-23259582221111077","doi-asserted-by":"publisher","DOI":"10.1007\/s40262-013-0093-2"},{"key":"bibr8-23259582221111077","doi-asserted-by":"publisher","DOI":"10.1086\/429321"},{"key":"bibr9-23259582221111077","doi-asserted-by":"publisher","DOI":"10.1097\/CCM.0b013e3181961bff"},{"key":"bibr10-23259582221111077","doi-asserted-by":"publisher","DOI":"10.1590\/S1413-86702009000300011"},{"key":"bibr11-23259582221111077","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.48.11.4473-4475.2004"},{"key":"bibr12-23259582221111077","doi-asserted-by":"publisher","DOI":"10.1590\/S1413-86702006000600003"},{"key":"bibr13-23259582221111077","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijid.2022.01.001"},{"key":"bibr14-23259582221111077","unstructured":"Adolescents. PoAGfAa. Guidelines for the use of antiretroviral agents in adults and adolescents with HIV. Department of Health and Human Services. 2020. http:\/\/aidsinfo.nih.gov\/contentfiles\/lvguidelines\/AdultandAdolescentGL.pdf"},{"issue":"1","key":"bibr15-23259582221111077","doi-asserted-by":"crossref","first-page":"1","DOI":"10.7448\/IAS.15.6.18264","volume":"15","author":"Eron J","year":"2012","journal-title":"J Int AIDS Soc."}],"container-title":["Journal of the International Association of Providers of AIDS Care (JIAPAC)"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/23259582221111077","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/23259582221111077","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/23259582221111077","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T22:50:08Z","timestamp":1777503008000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/23259582221111077"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,1]]},"references-count":15,"alternative-id":["10.1177\/23259582221111077"],"URL":"https:\/\/doi.org\/10.1177\/23259582221111077","relation":{},"ISSN":["2325-9582","2325-9582"],"issn-type":[{"value":"2325-9582","type":"print"},{"value":"2325-9582","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,1]]},"article-number":"23259582221111077"}}